The PAN Foundation signs stakeholder letter to Congress opposing legislation that would exclude cost-sharing assistance from counting towards patients’ out-of-pocket maximums

On behalf of patients we represent, we strongly oppose recent policy changes in the 2021 Notice of Benefit and Payment Parameters (NBPP) that would allow the exclusion of manufacturer cost-sharing assistance from counting towards patients’ out-of-pocket maximums in the commercial market. This policy will prevent patients from accessing the medications they depend upon and create unnecessary barriers to maintaining effective treatment plans, especially during the global Covid-19 pandemic.